These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 10496366)

  • 1. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
    Litton MJ; Dohlsten M; Rosendahl A; Ohlsson L; Søgaard M; Andersson J; Andersson U
    Br J Cancer; 1999 Sep; 81(2):359-66. PubMed ID: 10496366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
    Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M
    J Immunol; 1998 Jun; 160(11):5309-13. PubMed ID: 9605129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.
    Litton MJ; Dohlsten M; Hansson J; Rosendahl A; Ohlsson L; Kalland T; Andersson J; Andersson U
    Am J Pathol; 1997 May; 150(5):1607-18. PubMed ID: 9137087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
    Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
    Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
    Sundstedt A; Celander M; Hedlund G
    Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superantigens anergize cytokine production but not cytotoxicity in vivo.
    Sundstedt A; Dohlsten M; Hedlund G; Höidén I; Björklund M; Kalland T
    Immunology; 1994 May; 82(1):117-25. PubMed ID: 7913912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-gamma expression in CD8+ T cells regulated by IL-6 signal is involved in superantigen-mediated CD4+ T cell death.
    Atsumi T; Sato M; Kamimura D; Moroi A; Iwakura Y; Betz UA; Yoshimura A; Nishihara M; Hirano T; Murakami M
    Int Immunol; 2009 Jan; 21(1):73-80. PubMed ID: 19050105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
    Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
    Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.
    Litton MJ; Dohlsten M; Lando PA; Kalland T; Ohlsson L; Andersson J; Andersson U
    Eur J Immunol; 1996 Jan; 26(1):1-9. PubMed ID: 8566049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.
    Song K; Chang Y; Prud'homme GJ
    Gene Ther; 2000 Sep; 7(18):1527-35. PubMed ID: 11021590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
    Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
    J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells.
    Williams NS; Engelhard VH
    J Immunol; 1997 Sep; 159(5):2091-9. PubMed ID: 9278294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.
    Dohlsten M; Björklund M; Sundstedt A; Hedlund G; Samson D; Kalland T
    Immunology; 1993 Aug; 79(4):520-7. PubMed ID: 7691731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.
    Asnagli H; Schmitt-Verhulst AM; Guimezanes A
    J Immunol; 1997 May; 158(10):4533-42. PubMed ID: 9144464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T; Harada M; Tamada K; Abe K; Nomoto K
    Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response during tumor therapy with antibody-superantigen fusion proteins.
    Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M
    Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.
    Rosendahl A; Kristensson K; Hansson J; Ohlsson L; Kalland T; Dohlsten M
    Int J Cancer; 1998 Apr; 76(2):274-83. PubMed ID: 9537591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
    Dohlsten M; Hansson J; Ohlsson L; Litton M; Kalland T
    Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9791-5. PubMed ID: 7568219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo.
    Sundstedt A; Höiden I; Rosendahl A; Kalland T; van Rooijen N; Dohlsten M
    J Immunol; 1997 Jan; 158(1):180-6. PubMed ID: 8977189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.